Quetzal Chavez Castañeda

Dr. Quetzal Chavez Castañeda

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
RSRicardo Xopan Suárez-García
Ricardo Xopan Suárez-García
QCQuetzal Chavez Castañeda
Quetzal Chavez Castañeda
RORodrigo Orrico-Pérez
Rodrigo Orrico-Pérez
SVSebastián Valencia-Marin
Sebastián Valencia-Marin
ACAri Evelyn Castañeda-Ramírez
Ari Evelyn Castañeda-Ramírez
HCHector Ivan Saldivar Ceron
Hector Ivan Saldivar Ceron
DIALOGUE (DIagnostic AI Learning through Objective Guided User Experience) is a generative artificial intelligence (GenAI)-based training program designed to enhance diagnostic communication skills in medical students. In this single-arm pre–post study, we evaluated whether DIALOGUE could improve students’ ability to disclose a type 2 diabetes mellitus (T2DM) diagnosis with clarity, structure, and empathy. Thirty clinical-phase students completed two pre-test virtual encounters with an AI-simulated patient (ChatGPT, GPT-4o), scored by blinded raters using an eight-domain rubric. Participants then engaged in ten asynchronous GenAI scenarios with automated natural-language feedback. Seven days later, they completed two post-test consultations with human standardized patients, again evaluated with the same rubric. Mean total performance increased by 36.7 points (95% CI: 31.4–42.1; p < 0.001), and the proportion of high-performing students rose from 0% to 70%. Gains were significant across all domains, most notably in opening the encounter, closure, and diabetes specific explanation. Multiple regression showed that lower baseline empathy (β = −0.41, p = 0.005) and higher digital self-efficacy (β = 0.35, p = 0.016) independently predicted greater improvement; gender had only a marginal effect. Cluster analysis revealed three learner profiles, with the highest-gain group characterized by low empathy and high digital self-efficacy. Inter-rater reliability was excellent (ICC ≈ 0.90). These findings provide empirical evidence that GenAI-mediated training can meaningfully enhance diagnostic communication and may serve as a scalable, individualized adjunct to conventional medical education.

10 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
RGRicardo Xopan Suarez Garcia
Ricardo Xopan Suarez Garcia
QCQuetzal Chavez Castañeda
Quetzal Chavez Castañeda
RPRodrigo Orrico Pérez
Rodrigo Orrico Pérez
SVSebastián Valencia-Marin
Sebastián Valencia-Marin
ACAri Evelyn Castañeda-Ramírez
Ari Evelyn Castañeda-Ramírez
HCHector Ivan Saldivar Ceron
Hector Ivan Saldivar Ceron
Effective diagnostic communication—delivering a diagnosis with clarity, structure, and empathy—remains a challenging competency for many undergraduate medical students. This single-arm pre–post study evaluated a generative artificial-intelligence (GenAI) training module designed to improve diagnostic-communication performance. Thirty clinical-phase students completed two pre-test encounters in which they disclosed a type 2 diabetes mellitus (T2DM) diagnosis to a virtual patient powered by ChatGPT (GPT-4o) and were scored with an eight-domain rubric by blinded raters. They then undertook ten asynchronous GenAI scenarios with automated natural-language feedback, followed seven days later by two post-test consultations with human standardized patients assessed in real time with the same rubric. Mean total performance increased by 36.7 points (95 % CI: 31.4–42.1; p < 0.001), and the proportion of high-performing students rose from 0 % to 70 %. Gains were significant across all domains, most notably in opening the encounter, closure, and diabetes-specific explanation. Multiple regression showed that lower baseline empathy (β = –0.41, p= 0.005) and higher digital self-efficacy (β = 0.35, p= 0.016) inde-pendently predicted greater improvement; gender displayed only a marginal effect. Cluster analysis revealed three learner profiles, with the highest-gain cluster character-ised by low empathy and high digital self-efficacy. Inter-rater reliability was excellent (ICC ≈ 0.90). These findings provide empirical evidence that GenAI-mediated practice can produce meaningful, measurable enhancements in diagnostic-communication skills and may serve as a scalable, individualised adjunct to conventional clinical education.

Verified
Journal Article
Open access
PDF file
HCHector Ivan Saldivar Ceron
Hector Ivan Saldivar Ceron
DMDaniela Maldonado
Daniela Maldonado
QCQuetzal Chavez Castañeda
Quetzal Chavez Castañeda
AGAna Lorena Mercado Guzman
Ana Lorena Mercado Guzman
ALAngela Leon
Angela Leon
SONIA LEON-CABRERASONIA LEON-CABRERA
SONIA LEON-CABRERA
Oxyntomodulin (OXM), an endogenous proglucagon-derived peptide with dual glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) agonism, provides a physiological precedent for contemporary multi-receptor pharmacology. Recognition that GCGR signaling regulates not only hepatic glucose production but also amino acid turnover, lipid metabolism, substrate oxidation, and energy expenditure prompted the development of engineered GLP-1R/GCGR co-agonists, including cotadutide, mazdutide, survodutide, and pemvidutide. Retatrutide extends this strategy by integrating GIPR, GLP-1R, and GCGR agonism within a single long-acting peptide and has produced substantial improvements in body weight, glycemic control, and cardiometabolic parameters in phase 2 and phase 3 trials. This review examines the evolutionary and structural relationships of the proglucagon–Class B1 GPCR system, OXM biosynthesis and receptor pharmacology, the mechanistic rationale for therapeutic GCGR agonism, and the molecular and clinical development of dual and triple agonists. We further address receptor balance, the GIPR agonism–antagonism paradox, receptor-specific causal attribution, and the unresolved limitations of translating molecular pharmacology into durable clinical benefit. Finally, we propose an Activity–Exposure–Context framework for interpreting polyagonist pharmacology and discuss prospective enteroinsular phenotyping using standardized mixed-meal testing as a testable strategy to investigate interindividual variability in therapeutic response.

5 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
HCHector Ivan Saldivar Ceron
Hector Ivan Saldivar Ceron
DMDaniela Maldonado
Daniela Maldonado
QCQuetzal Chavez Castañeda
Quetzal Chavez Castañeda
AGAna Lorena Mercado Guzman
Ana Lorena Mercado Guzman
ALAngela Leon
Angela Leon
SONIA LEON-CABRERASONIA LEON-CABRERA
SONIA LEON-CABRERA
Oxyntomodulin (OXM), an endogenous proglucagon-derived peptide with dual glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) agonism, provides a physiological precedent for contemporary multi-receptor pharmacology. Recognition that GCGR signaling regulates not only hepatic glucose production but also amino acid turnover, lipid metabolism, substrate oxidation, and energy expenditure prompted the development of engineered GLP-1R/GCGR co-agonists, including cotadutide, mazdutide, survodutide, and pemvidutide. Retatrutide extends this strategy by integrating GIPR, GLP-1R, and GCGR agonism within a single long-acting peptide and has produced substantial improvements in body weight, glycemic control, and cardiometabolic parameters in phase 2 and phase 3 trials. This review examines the evolutionary and structural relationships of the proglucagon–Class B1 GPCR system, OXM biosynthesis and receptor pharmacology, the mechanistic rationale for therapeutic GCGR agonism, and the molecular and clinical development of dual and triple agonists. We further address receptor balance, the GIPR agonism–antagonism paradox, and the unresolved attribution of clinical effects to individual receptor components. Finally, we propose an Activity–Exposure–Context framework for interpreting polyagonist pharmacology and discuss prospective enteroinsular phenotyping using standardized mixed-meal testing as a testable strategy to investigate interindividual variability in therapeutic response.